USE OF EPAC1 ACTIVATORS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES
Chronic Kidney Disease (CKD) is a major burden of public health affecting millions of people around the world. It is rising in prevalence with high public health costs and is associated with a high degree of morbidity and mortality. Here, the inventors determined whether the exchange protein directly activated by cAMP 1 (Epac1) contributed to severe glomurelonephritis (GN) induced by injecting nephrotoxic serum (NTS) in mice. Treatment of GN mice with a pharmacological activator of Epac1, 8-(4-Chlorophenylthio)-2'-Omethyladenosine-3', 5'- cyclic monophosphate (8-pCPT) improved functional and structural renal parameters, and reduced renal inflammation after NTS injection. Taken together, these findings suggest that Epac1 activation is an attractive and promising pharmacological intervention for the therapeutic treatment of CKD. Thus the present invention relates to use of Epac1 activators for the treatment of chronic kidney diseases.